Do GLP-1 medications protect kidney function?

Yes, GLP-1 medications demonstrate significant kidney protective effects beyond glucose control. Semaglutide reduced the risk of kidney disease progression and cardiovascular death by 24% in the FLOW trial involving patients with type 2 diabetes and chronic kidney disease. Liraglutide and dulaglutide also show kidney benefits in clinical trials. The mechanisms include reduced inflammation, improved blood pressure control, weight loss, and direct effects on renal hemodynamics. The KDIGO guidelines now recommend GLP-1 agonists with proven kidney benefits as preferred therapy for type 2 diabetes patients with CKD or high risk of CKD progression, regardless of HbA1c levels.